Clinical trials: Lung Neoplasm Malignant
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Lung Neoplasm, Carcinoma, Non-Small-Cell Lung
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either…
- Conditions
- Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT05153408
- Testing
- BLU-701, osimertinib, carboplatin
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Blueprint Medicines Corporation
Pulmonary Cancer
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
- Trial name
- NCT00344773
- Testing
- Gefitinib
- Where
- 2 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Lung Cancer
A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
This Phase 2 study is an open-label, single-arm trial where each patient is his/her own "intrapatient" control. All patients will receive a single dose of pegsitacianine prior to standard of care surgery.
- Trial name
- NCT05048082
- Testing
- pegsitacianine, Tumor resection surgery
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- OncoNano Medicine, Inc.
Malignant Pleural Mesothelioma
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes the protein ICP34.5.
- Trial name
- 1716-12 (NCT01721018)
- Testing
- HSV1716 Intra-pleural delivery
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Virttu Biologics Limited
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease.
- Trial name
- NCT01680991
- Testing
- Obinutuzumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Malignant Neoplasm
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors.
- Trial name
- NCT06385925
- Testing
- TSN1611
- Where
- 19 sites in United States, China
- Volunteers
- 440 people
- Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor
- Trial name
- NCT05099549
- Testing
- AFM24, SNK01
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- NKGen Biotech, Inc.
Malignant Solid Tumor
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug…
- Trial name
- NCT01606748
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors.
- Trial name
- NCT01325558
- Testing
- ALT-836 in combination with gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Altor BioScience
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Advanced Cancer, Metastatic Cancer
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung
- Trial name
- NCT04975256
- Testing
- MRTX849, BI 1701963
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mirati Therapeutics Inc.
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Lung Neuroendocrine Neoplasm
Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
The present study is designed to collect safety/tolerability data and explore the efficacy of RAD001 in advanced pulmonary neuroendocrine tumor in Chinese patients.
- Trial name
- \MACS1304 (NCT01324492)
- Testing
- RAD001
- Where
- 4 sites in China
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor…
- Trial name
- NCT02414139
- Testing
- Capmatinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology
This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening…
- Trial name
- NCT02512757
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Innovis LLC